Jiangsu Sinopep-Allsino Biopharmaceutical Past Earnings Performance
Past criteria checks 3/6
Jiangsu Sinopep-Allsino Biopharmaceutical has been growing earnings at an average annual rate of 23.7%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 23.5% per year. Jiangsu Sinopep-Allsino Biopharmaceutical's return on equity is 9.3%, and it has net margins of 17.6%.
Key information
23.7%
Earnings growth rate
15.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 23.5% |
| Return on equity | 9.3% |
| Net Margin | 17.6% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Jiangsu Sinopep-Allsino Biopharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,181 | 208 | 293 | 171 |
| 31 Dec 23 | 1,034 | 163 | 273 | 125 |
| 30 Sep 23 | 979 | 168 | 255 | 105 |
| 30 Jun 23 | 784 | 136 | 220 | 76 |
| 31 Mar 23 | 725 | 134 | 207 | 77 |
| 31 Dec 22 | 651 | 129 | 193 | 69 |
| 30 Sep 22 | 576 | 95 | 181 | 68 |
| 30 Jun 22 | 603 | 99 | 174 | 65 |
| 31 Mar 22 | 612 | 92 | 163 | 61 |
| 31 Dec 21 | 644 | 115 | 152 | 63 |
| 30 Sep 21 | 642 | 113 | 151 | 62 |
| 30 Jun 21 | 660 | 126 | 139 | 66 |
| 31 Mar 21 | 687 | 159 | 136 | 66 |
| 31 Dec 20 | 567 | 123 | 122 | 61 |
| 30 Sep 20 | 481 | 94 | 112 | 52 |
| 30 Jun 20 | 425 | 74 | 94 | 50 |
| 31 Mar 20 | 353 | 46 | 93 | 45 |
| 31 Dec 19 | 372 | 49 | 89 | 48 |
| 30 Sep 19 | 313 | 40 | 79 | 56 |
| 30 Jun 19 | 266 | 31 | 83 | 47 |
| 31 Mar 19 | 298 | 59 | 74 | 39 |
| 31 Dec 18 | 256 | 44 | 72 | 35 |
| 30 Sep 18 | 284 | 66 | 71 | 29 |
| 30 Jun 18 | 286 | 71 | 63 | 25 |
| 31 Mar 18 | 245 | 46 | 56 | 23 |
| 31 Dec 17 | 229 | 42 | 54 | 18 |
| 30 Sep 17 | 156 | -7 | 63 | 7 |
| 30 Jun 17 | 104 | -46 | 79 | 4 |
| 31 Mar 17 | 26 | -66 | 75 | 0 |
| 31 Dec 16 | 9 | -75 | 72 | 0 |
| 30 Sep 16 | 6 | -53 | 52 | 0 |
| 30 Jun 16 | 3 | -33 | 31 | 0 |
| 31 Mar 16 | 6 | -32 | 29 | 0 |
| 31 Dec 15 | 9 | -30 | 27 | 0 |
| 31 Dec 14 | 0 | -25 | 19 | 0 |
Quality Earnings: 688076 has a high level of non-cash earnings.
Growing Profit Margin: 688076's current net profit margins (17.6%) are lower than last year (18.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688076's earnings have grown significantly by 23.7% per year over the past 5 years.
Accelerating Growth: 688076's earnings growth over the past year (55.4%) exceeds its 5-year average (23.7% per year).
Earnings vs Industry: 688076 earnings growth over the past year (55.4%) exceeded the Pharmaceuticals industry 8.5%.
Return on Equity
High ROE: 688076's Return on Equity (9.3%) is considered low.